Bunny Hills
L1 2.0 tech hr6624-119

Biological Intellectual Property Protection Act of 2025

Why China-relevant: the People's Republic of China is conducting a systematic campaign to access and exploit sensitive United States data and intellectual property to modernize its military ... the Secretary shall ... require a license for the export, reexport, or in-country transfer to a foreign entity of concern of a digital sequence of

Sponsor: Davidson, Warren (R-OH) · 11 cosponsors bipartisan

Path to becoming law

  1. Introduced
  2. Passed committee
  3. Passed House next step
  4. Passed Senate
  5. Sent to President
  6. Became law

done next step still ahead

Legislative timeline — dated actions so far

  1. Filed
  2. Advanced in committee
Stage: Reported out of committee

2% to become law · 9% to clear committee

  • + Broad cosponsorship (11 cosponsors)
  • + Sponsored by a member of the majority party
  • + Has an identical companion bill in the other chamber
  • + Bipartisan support (3/11 cosponsors from across the aisle)

Legislative likelihood — a tracking indicator, not investment advice.

Signals — secondary, directional

PRC retaliation risk low Hawkishness 1–5 4

Directional context (see Methodology); the pinned, high-confidence axes are relevance and asset impact.

Shares that might be influenced

Each sector shows a direction (which way its China-related names are pushed) and, for precise mappings, how hard this bill hits the sector — rated marginal → very strong (1–5). Hover any chip for its definition. The headline 0–5 impact is at the top of the card.

China Pharma negative modest (2/5) precise 806 names

Export-control license requirement on synthetic DNA/RNA sequences to Chinese entities of concern, restricting Chinese biotech (e.g., BGI/WuXi) access to US synthetic-bio IP

Ticker Name (Local) Name (EN) Restriction Lists
688235.SS 百济神州 BEONE MEDICINES
600276.SS 恒瑞医药 HENGRUI PHARMA
603259.SS 药明康德 WuXi AppTec
3692.HK 翰森制药 Hansoh Pharmaceutical Group Company Limited
300760.SZ 迈瑞医疗 MR
2269.HK 药明生物 WUXI BIOLOGICS (CAYMAN) INC.
1801.HK 信达生物 Innovent Biologics, Inc.
6618.HK 京东健康 JD Health International Inc.
6990.HK 科伦博泰生物 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
9926.HK 康方生物 Akeso,Inc.
+796 more